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This study describes the characteristics of 31 children with congenital toxoplasmosis chil-
dren  admitted to the University Hospital of Londrina, Southern Brazil, from 2000 to 2010. In
total, 23 (85.2%) of the mothers received prenatal care but only four (13.0%) were treated for
toxoplasmosis. Birth weight was <2500 g in 37.9% of the infants. During the ﬁrst month of life,
physical examination was normal in 34.5%, and for those with clinical signs and symptoms,
the  main manifestations were hepatomegaly and/or splenomegaly (62.1%), jaundice (13.8%),
and  microcephaly (6.9%). During ophthalmic examination, 74.2% of the children exhibited
injuries, 58.1% chorioretinitis, 32.3% strabismus, 19.4% microphthalmia, and 16.2% vitre-
itis.  Anti-Toxoplasma gondii IgM antibodies were detected in 48.3% of the children. Imaging
brain evaluation was normal in 44.8%; brain calciﬁcations, hydrocephaly, or both conditions
were observed in 27.6%, 10.3%, and 17.2%, respectively, of the patients. Patients with cere-
brospinal ﬂuid protein ≥ 200 mg/dL presented more brain calciﬁcations (p = 0.0325). Other
sequelae were visual impairment (55.2% of the cases), developmental delay (31.0%), motor
deﬁcit (13.8%), convulsion (27.5%), and attention deﬁcit (10.3%). All patients were treatedrimewith  sulfadiazine, pyeffects. The results demo
toxoplasmosis during pre
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1413-8670/$ – see front matter © 2014 Elsevier Editora Ltda. All rights r
http://dx.doi.org/10.1016/j.bjid.2013.11.009thamine, and folinic acid, and 55.2% of them exhibited adversenstrate the signiﬁcance of the early diagnosis and treatment of
gnancy to reduce congenital toxoplasmosis and its consequences.
© 2014 Elsevier Editora Ltda. All rights reserved.
iversity of Londrina, University Hospital, Street Robert Koch, 60,
eserved.
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ntroduction
oxoplasmosis is a worldwide infection caused by the proto-
oan Toxoplasma gondii (T. gondii),  an obligatory intracellular
arasite.1 In Central and South America, 50–80% of individuals
re seropositive for IgG antibodies against T. gondii,  indicating
heir previous exposure to this parasite.2 The prevalence of
his infection acquired during pregnancy ranges from 10.3%
o 75.2% in different countries.3–7 In Brazil, the seroprevalence
f anti-T. gondii IgG antibodies ranges from 49.2% to 91.6%,8–10
nd the incidence of congenital toxoplasmosis varies from 0.3
o 5.0 per 1000 births.11–13
The risk of fetal transmission depends on factors, such
s the maternal immune response, the gestational age at
nfection, and the parasite virulence. The risk of congenital
ransmission varies from up to 2% at the periconceptional
eriod, 10–25% in the ﬁrst trimester of pregnancy, 30–45% in
he second trimester, 60–65% in the third trimester, and up
o 80% before childbirth.1 However, the severity of congenital
isease is high when transmission occurs in the beginning of
he pregnancy and decreases with gestational age.1,2,4,7,8
The diagnosis of toxoplasmosis acquired during pregnancy
s based on laboratory tests because more  than 90% of infected
regnant women are asymptomatic. When clinical manifesta-
ions are present, in general, they are nonspeciﬁc and include
ever, headaches, myalgia, lymphadenopathy, and rash.14
The majority of children with congenital toxoplasmo-
is do not exhibit signs or symptoms at birth, presenting
nstead as subclinical infections; nevertheless, infected chil-
ren are at risk of developing late sequelae, mainly ocular
nd neurological. For the symptomatic children, the severity
f clinical manifestations is related to the trimester of preg-
ancy when transmission occurred, as follows: fetal death in
he ﬁrst trimester; retinochoroiditis, microcephaly, and men-
al retardation in the second trimester; and lymphadenopathy,
epatosplenomegaly, eye injuries, and brain calciﬁcations in
he third trimester.15 All of the children whose mothers pre-
ented acute toxoplasmosis during pregnancy, symptomatic
r not, may have congenital toxoplasmosis. Children born
ith signals or symptoms of congenital disease are also at risk
nd should undergo serological investigation to detect speciﬁc
nti-T. gondii antibodies.15
The purpose of this study was to describe the demographic,
linical, and laboratory characteristics of children with con-
enital toxoplasmosis that received treatment for congenital
oxoplasmosis at one medical center in southern Brazil.
aterials  and  methods
opulation  and  study  design
he study included a retrospective cohort of 236 medical
ecords of suspected congenital toxoplasmosis from the Out-
atient Reference Centre for Pediatric Infectious Diseases,
hich is the reference service for congenital toxoplasmosis
t the Outpatient Clinical Hospital, University of Londrina,
araná State, Brazil. The study identiﬁed 31 cases of con-
enital toxoplasmosis that occurred from January 2000 to4;1 8(4):364–371 365
December 2010. This study was approved by the Ethical Com-
mittee Involving Humans from the University of Londrina,
Londrina, Paraná, Brazil.
Diagnostic  criteria
Cases were deﬁned as congenital toxoplasmosis when the
infant exhibited one of the following features: anti-T. gondii
IgM and/or IgA antibodies after 10 days of life, persis-
tently elevated or increasing titers of IgG anti-T. gondii
(after three-week intervals between the samples), seroposi-
tive for IgG after 12 months of life, retinochoroiditis and/or
hydrocephaly/cerebral calciﬁcations, and anti-T. gondii IgG
seropositivity and response to speciﬁc treatment.16
During the period of the study, anti-T. gondii IgG antibod-
ies were detected by indirect immunoﬂuorescence (IFI) with
T. gondii ﬁxed on a glass slide.17 For the detection of anti-T.
gondii IgM antibodies, the methods varied in the period eval-
uated, but included indirect enzyme immunoassay (ELISA),
chemiluminescence, and IgM capture ELISA.
Statistical  analysis
Data were recorded in a database, and the statistical analy-
sis was performed using the Epi Info 3.4.3 and GraphPadPrism
5.00 software. Continuous variables were expressed in mini-
mum and maximum values, mean, standard deviation, and
median. Categorical variables were reported in absolute fre-
quency (n) and percentage (%). Comparisons between groups
of categorical variables were performed by Chi-square analysis
or Fisher’s exact test, when appropriate. An odds ratio (OR) and
95% conﬁdence interval (CI) were also calculated. The results
were considered signiﬁcant when the p-value was less than
0.05 (5%).
Results
Description  of  the  population
Of the 31 children evaluated, 20 (64.5%) were male and 11
(35.5%) were female. Their birth weights ranged from 1150
to 3800 g (median 2585 g), and 11 children (37.9%) had birth
weights < 2500 g. Gestational age at delivery ranged from 26.2
to 41 weeks (median 36 weeks). Maternal age ranged from 14 to
42 years (median 26 years), and 23/31 (85.2%) pregnant women
received prenatal care.
Clinical  analysis  of  pregnant  women
Among the 31 pregnant women evaluated, 16 (51.6%) did
not have a record of any clinical symptom, eight (25.8%)
were asymptomatic, and seven (22.5%) showed symptoms,
such as fever (6.5%), adenomegaly (6.5%), ﬂu-like symptoms
(6.5%), and myalgia (3.2%). The toxoplasmosis infection was
not diagnosed in 20/31 (64.5%) during pregnancy. Four women
(12.9%) had not received prenatal care, and 16 (51.6%) had a
serology requested. Eleven (35.5%) pregnant women were sus-
pected cases of recent T. gondii infection, indicated by positive
tests for IgM anti-T. gondii.  However, this suspicion was not
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Table 1 – Clinical manifestations presented by children with congenital toxoplasmosis attended at the Outpatient Clinic
Hospital of the State University of Londrina, Londrina, Paraná, from January 2000 to December 2010.
Clinical manifestations At birth (n = 20) During the ﬁrst month of
life (n = 29)
n (%) n (%)
Asymptomatic 10 (50.0) 10 (34.5)
Symptomatic 10 (50.0) 19 (65.5)
Hepatosplenomegaly 8 (40.0) 13 (44.8)
Jaundice 0 (0.0) 4 (13.8)
Esplenomegaly 1 (5.0) 3 (10.3)
Hepatomegaly 0 (0.0) 2 (6.9)
Microcephaly 1 (5.0.) 2 (6.9)
0.0)
5.0) 
0.0) Fever 0 (
Macrocephaly 1 (
Adenomegaly 0 (
conﬁrmed by other tests or serial samples, and they were not
treated for toxoplasmosis. Only four (12.9%) pregnant women
infected with T. gondii received speciﬁc treatment (two with
sulfadiazine, pyrimethamine, and folinic acid, and two with
spiramycin). The other 27 (87.0%) pregnant women received
no toxoplasmosis treatment.
Clinical  analysis  of  children
Twenty children (64.5%) were examined at birth, and nine
(29.0%) were evaluated in the ﬁrst month of life. Two children
(6.5%) were referred without any record of signs or symptoms.
One child (3.2%) was evaluated for the ﬁrst time after nine
months of life with chorioretinitis, cataract, and microph-
thalmia. One child (3.2%) was ﬁrst evaluated at ﬁve years
of age and presented with sequelae of congenital infection,
such as scars of chorioretinitis, hyperactivity, attention deﬁcit,
and precocious puberty. The frequency of clinical manifesta-
tions of congenital toxoplasmosis at birth and during the ﬁrst
month of life is shown in Table 1.
The clinical classiﬁcation of the disease presented by
these 31 children were as follows: 29 (93.5%) were classiﬁed
in ﬁrst month of life; four (13.8%) were subclinical without
Table 2 – Ophthalmologic manifestations observed during the ﬁ
with congenital toxoplasmosis treated at the Outpatient Clinic 
Paraná, from January 2000 to December 2010.
Ophthalmologic manifestations During the
life
No manifestationsa 9
Chorioretinitis 16
Strabismusb,c 1
Microphthalmia 2
Vitreitis 5
Uveitis 3
Cataractd 1
Nystagmuse 0
a In one patient the lesion of chorioretinitis improved without leaving a s
b One (3.5%) patient exhibited association of strabismus, cataract, and mi
c Seven (22.6%) patients with strabismus associated with chorioretinitis an
and/or microphthalmia after the ﬁrst month of life;
d One (3.5%) patient presented cataract associated with chorioretinitis in 
e Three (9.7%) patients presented nystagmus associated with chorioretini1  (3.4)
1 (3.4)
0 (0.0)
signs or symptoms during infancy; 24 (82.8%) exhibited
neonatal disease with clinical manifestations, such as ocu-
lar lesion (chorioretinitis) and/or neurological impairment
(hydrocephaly and/or calciﬁcation); and one (3.2%) was ini-
tially asymptomatic but presented fever and splenomegaly
at four months of age without neurological or ophthalmic
impairment. Among the children with subclinical infections,
one (3.2%) had strabismus and convulsions at four years of
age.
The ophthalmic manifestations observed in the children
during the ﬁrst month of life and after this period are described
in Table 2.
Of all the patients, one (3.2%) child was exposed but
uninfected with HIV-1, and one (3.2%) was co-infected with
HIV-1. One child (3.2%) was co-infected with HIV-1 and
cytomegalovirus (CMV), and three children (9.7%) were co-
infected with CMV.  In one infant with persistent hepatitis,
a CMV infection was diagnosed by polymerase chain reac-
tion; out of three infants with anti-CMV IgM antibody, one
presented with giant cell hepatitis.
The frequency of sequelae was elevated among the chil-
dren with congenital toxoplasmosis, as described in Table 3.
Two (6.2%) children presented with endocrine dysfunctions,
rst month and after the ﬁrst month of life in children
Hospital of the State University of Londrina, Londrina,
 ﬁrst month of
 (n = 29)
After  the ﬁrst month
of life (n = 31)
n (%) n (%)
 (31.0) 8 (25.8)
 (55.2) 18 (58.1)
 (3.5) 10 (32.3)
 (6.9) 6 (19.4)
 (17.2) 5 (16.2)
 (10.3) 3 (9.7)
 (3.5) 3 (9.7)
 (0.0) 3 (9.7)
car;
crophthalmia in the ﬁrst month of life;
d three (9.7%) patients presented strabismus associated with cataract
the ﬁrst month of life.
tis
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Table 3 – Sequelaes detected in children with congenital
toxoplasmosis attended at Outpatient Clinic Hospital of
the State University of Londrina, Londrina, Paraná, from
January 2000 to December 2010.
Sequelae Children (n = 29)
n %
Not detectablea 9 31.1
Detectable 20 68.9
Visual 16 55.2
Delay of psychomotor development 9 31.0
Convulsionb 8 27.5
Motor dysfunction 4 13.8
Hyperactivity and/or deﬁcit of attention 3 10.3
Precocious puberty 2 6.9
Hypothyroidism 1 3.4
Ventricular peritoneal shunt 1 3.4
Hearing damagec 3 50.0
a Two children lost the follow-up.
b Four children presented convulsion during the ﬁrst month of life.
c Detected in six children, all of them with hearing damage also
presented concomitant neurological sequelae; 1/31 (3.4%) child
co-infected with HIV-1 who died with 12 months of life due to
o
o
L
L
p
r
r
a
(
s
p
e
>
iherpetic encephalitis and severe sepsis.
ne with central precocious puberty and the other with sec-
ndary hypothyroidism.
aboratory  and  diagnostic  data
umbar puncture for cerebrospinal ﬂuid (CSF) collection was
erformed on 21 (67.7%) children. In the CSF, leukocytes
anged from 2 to 149 cells/mm3 (median 19 cells/mm3), eryth-
ocytes ranged from 3 to 26,400 cells/mm3 (median 56/mm3),
nd the protein concentration ranged from 34 to 1594 mg/dL
median 104 mg/dL). Although six (28.6%) CSF samples pre-
ented elevated erythrocyte count (>1000/mm3), high CSF
rotein observed could not be explained only by the pres-
nce of these cells. Six patients (28.6%) presented CSF protein
180 mg/dL, but erythrocyte counts were > 2500 cells/mm3
n only one patient (erythrocyte = 26,400 cells/mm3 and
Table 4 – Results of imaging brain exams from children with co
ﬂuid protein levels, attended at Outpatient Clinic Hospital of th
January 2000 to December 2010.
CSF protein (mg/dL)a Imaging brain exam
With calciﬁcation n/total
of cases (%)
Without c
n/total o
≥200
<200
5/5  (1000)
5/14 (35.7)
0/5  (0
9/14 
≥180
<180
5/6 (83.3)
5/13 (38.5)
1/6  (1
8/13 
≥150
<150
6/8 (75.0)
4/11 (36.4)
2/8  (2
7/11 
CSF, cerebrospinal ﬂuid.
a The frequencies of imaging brain exams were distributed according the 
b Fisher’s exact test.4;1 8(4):364–371 367
protein = 879 mg/dL). Of the two patients (9.5%) with CSF
protein >1 g/dL, the erythrocyte count was lower than
35 cells/mm3. In total, 19 patients (90.4%) who  underwent
lumbar puncture for CSF collection also performed imaging
exams. Of these patients, 10 (52.6%) had brain calciﬁcations,
and two (10.5%) presented with brain calciﬁcations associ-
ated with hydrocephaly. There was an association between the
presence of ≥200 mg/dL protein in CSF and brain calciﬁcations
(p = 0.0352) (Table 4).
Brain computed tomography (CT) and ultrasonography
(USG) results are presented in Table 5.
Fifteen of the 23 (65.2%) patients presented ophthalmic
injuries and concomitant brain lesions, while 2/17 (11.8%)
patients did not present ophthalmic injuries but showed CNS
lesions (p = 0.1897, OR: 4.68, 95% CI: 0.73–29.85). There was no
association between the presence of eye injuries and changes
in brain imaging (hydrocephaly and calciﬁcations). In 20 male
patients, 15 (75%) showed eye injuries, while among 11 female
patients, nine (81.8%) showed eye injuries (p = 1.00, OR: 0.66,
95% CI: 0.10–4.18).
Overall, 15 (48.3%) children showed detectable serum
levels of anti-T. gondii IgM antibodies. Two patients were
seronegative for anti-T. gondii IgM in the ﬁrst sample and
seropositive in the second sample. The serum levels of
anti-T. gondii IgG were obtained during the ﬁrst week and
the ﬁrst, 3rd, 6th, 9th and 12th months of life. During the
ﬁrst week of life, the values ranged from 1:16 to 1:128,000
[mode = 1:64 (20%) and 1:4000 (20%)]; in the 2nd sample,
the levels ranged from 1:1024 to 1:128,000 [mode = 1:8000
(33.3%)]. In the 3rd serial blood sample, the values ranged
from 1:16 to 1:64,000 [mode = 1:64,000 (27.3%)], and in the
4th serial blood sample, they ranged from 1:16 to 1:128,000
[mode = 1:32,000 (20%)]. In the 5th serial blood sample, the
values ranged from 1:256 to 1: 16,000 [mode = 1:4000 (40%)],
and in the 6th serial sample, they ranged from 1:16 to
1:32,000 [mode = 1:16 (33.3%)]. During serological evolution
of the patients, the rebound effect was detected in nine
patients after discontinuing treatment and was detected by
an increased level of serum anti-T. gondii IgG between 15 and
18 months of life, ranging from 1:16 to 1:128,000 [mode = 1:1024
(28.6%)].
ngenital toxoplasmosis, according to the cerebrospinal
e State University of Londrina, Londrina, Paraná, from
s Odds ratio (95% CI) p valueb
alciﬁcation
f cases (%)
.0)
(64.3)
19.00
0.8729–413.6
0.0325
6.7)
(61.5)
8.00
0.7107–90.05
0.1409
5.0)
(63.6)
5.25
0.6979–39.50
0.1698
different cut-off values of CSF protein levels; CI: conﬁdence interval.
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Table 5 – Results obtained in brain computed tomography and ultrasonography performed during the ﬁrst month of life
of children with congenital toxoplasmosis, attended at Outpatient Clinic Hospital of the State University of Londrina,
Londrina, Paraná, from January 2000 to December 2010.
Results Brain CT (n = 24) Brain USG (n = 13) Odds ratio (95% CI) p value
n (%) n (%)
No changes 11 (45.8) 6 (46.1) 1.182 (0.2950–4.735) 0.8134*
Hydrocephalus 0 (0.0) 6 (46.1) 0.02355 (0.00118–0.4688) 0.0007†
Calciﬁcation 8 (33.3) 0 (0.0) 13.91 (0.7337–263.7) 0.0324†
Hydrocephalus and calciﬁcation 5 (20.8) 0 (0.0) 7.615 (0.3877–149.6) 0.1398†
CT, computed tomography; USG, ultrasonography; CI, conﬁdence interval.
∗ Chi-square test, p < 0.05.
transmission and the severity of fetal consequences, which
justiﬁes the screening of all pregnant women with serologi-
cal tests that detect anti-T. gondii IgG and IgM antibodies.15,18
Table 6 – Major adverse effects observed among children
with congenital toxoplasmosis during the treatment
with sulfadiazine, pyrimethamine, and folinic acid,
attended at Outpatient Clinic Hospital of the State
University of Londrina, Londrina, Paraná, from January
2000 to December 2010.
Adverse effects Children (n = 29)
n %
Mild neutropeniaa (1001–1499 cells/mm3) 4 13.8
Moderate neutropenia b (501–1000 cells/mm3) 7 24.1
Severe neutropeniac (≤500 cells/mm3) 2 6.9
Mild megaloblastic anemia (Hemoglobin:
10.1–11.9 g/dL)
1  3.5
Moderate megaloblastic anemia (Hemoglobin:
8.1–10.0 g/dL)
0  0.0
Severe megaloblastic anemiac (Hemoglobin:
≤8.0 g/dL)
1  3.5
Mild thrombocytopeniac (platelets
101,000–140,000/mm3)
1  3.5
Moderate thrombocytopeniad (platelets
51,000–100,000/mm3)
1  3.5
Severe thrombocytopenia
(platelets ≤ 50,000/mm3)
0  0.0
Mild hepatitis (AST and/or ALT ≤ two times the
reference value)
3  10.3
Moderate hepatitis (AST and/or ALT > two times
the reference value, and normal protrombine
time test)
1  3.5
Severe hepatitis (protrombine time test < 50.0%
or INR > 1.3)
0  0.0
AST, aspartate aminotransferase; ALT, alanine aminotransferase;
INR, international normalized ratio.
a 1 patient received zidovudine (AZT) and ganciclovir concomi-
tantly, 1 patient received ganciclovir concomitantly.
b 1 patient received zidovudine concomitantly.
c† Fisher’s exact test, p < 0.05.
Treatment  data
Children’s age for initiation of toxoplasmosis treatment
ranged from one day to nine months (median age, one month).
Among the 29 infants who received speciﬁc therapy, 28 (90.3%)
received sulfadiazine, pyrimethamine, and folinic acid, and
one (3.2%) received spiramycin. Ten infants (34.5%) were
treated with corticosteroids (prednisone) associated with spe-
ciﬁc therapy when their CSF protein was ≥1 g/dL and/or when
they presented chorioretinitis with macular injury. Two chil-
dren (6.5%) were not treated. One ﬁve-year-old child was
referred to the reference service but the mother of the other
child refused treatment, and the infant had no clinical follow-
up. The infant who was treated with spiramycin for three
months at another health service was switched to put on
sulfadiazine, pyrimethamine, and folinic acid. Among the 29
(93.5%) treated infants, the treatment was temporarily mod-
iﬁed in nine (31.0%): two children (6.9%) were treated with
clindamycin, one (3.5%) with pyrimethamine and folinic acid,
and six (20.7%) were treated with spiramycin.
Regarding the use of associated therapies, three children
were treated with ganciclovir, two with zidovudine (AZT), and
one with ganciclovir associated with AZT.
During the treatment for toxoplasmosis, 16 of the 29
patients (55.2%) presented adverse effects (Table 6). Six
patients (37.5%) received a combination of therapies. Four
patients received AZT, and three patients received ganci-
clovir. One infant treated with spiramycin was presented with
frequent vomiting that improved with the reintroduction of
sulfadiazine, pyrimethamine, and folinic acid. Hematologi-
cal changes, including mild neutropenia and/or mild anemia,
were reversed with an increased daily dose of folinic acid.
When reverted to sulfadiazine, pyrimethamine, and folinic
acid therapy, patients who temporarily received modiﬁed
treatment because of adverse effects were treated with a
higher daily dose of folinic acid.
Discussion
As clinical signs and symptoms in pregnancy are limiting
factors for diagnosis, systematic serological screening tests
during pregnancy are important yet controversial tools, par-
ticularly in regions where immunoreactivity before pregnancy
is low and the risk for seroconversion during the pregnancy ishigh. However, early diagnosis of T. gondii infection and appro-
priate anti-parasitic treatment are measures that can reduce1 patient that received zidovudine concomitantly presented
severe neutropenia, severe megaloblastic anemia, and mild
thrombocytopenia.
d 1 patient received ganciclovir concomitantly.
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 study from southern Brazil showed that 47.8% of pregnant
omen were seropositive for T. gondii,  indicating previous
xposure to the parasite, and 27.2% were not correctly diag-
osed for T. gondii during pregnancy due to some factors, such
s lack of prenatal care or because the serological tests were
ot performed.13 Despite the good prenatal care for pregnant
omen evaluated in the present study, serological investiga-
ion for toxoplasmosis was not performed in the majority of
regnant women.
The high frequency of prematurity and the low birth weight
f infants observed in the present study are consistent with
revious Brazilian studies that showed birth weight of infected
hildren varying from 1290 to 3790 g.13,19–24
Congenital toxoplasmosis may present different clinical
orms, including subclinical infection, disease during the
eonatal period, severe disease, mild disease in the ﬁrst
onth of life, sequelae or reactivation of previously undiag-
osed infection.15
In newborns and symptomatic infants, clinical presenta-
ion is divided into neurological and generalized forms. One
eurological form, Sabin’s tetrad, results from fetal infection
t the beginning of the pregnancy and produces diffuse cere-
ral calciﬁcations, chorioretinitis, convulsions, hydrocephaly
r microcephaly. The generalized form results from infection
uring late pregnancy and is characterized by chorioretinitis,
hanges in CSF, hepatosplenomegaly, jaundice, lymphade-
omegaly, thrombocytopenia, and anemia.15,18
Brazilian studies carried out between 1990 and 2010
howed that early clinical manifestations were present in
6–100% of the children evaluated. Chorioretinitis was present
n 67–80%, and brain calciﬁcations were observed in 11–100%
f the cases, many  of them without prenatal treatment.13,19–25
ther studies reported the presence of hydrocephaly in
.3–21% of children and microcephaly in 5.3% of the evaluated
hildren.24,26
Ocular injuries are not totally dependent on the gestational
ge of maternal infection; they may result in severe cases of
horioretinitis, even if the infection is acquired in the second
alf of the pregnancy. Furthermore, the risk of chorioretinitis
 the most frequent sequela – persists for many  years.27 Of the
cular manifestations among Brazilian children with congen-
tal toxoplasmosis, 29–100% presented chorioretinitis during
he evolution of the disease, with 12–84% presenting bilateral
njuries. Frequent symptoms include microphthalmia (9–25%
f cases), strabismus (12–60%), nystagmus (3–47%), cataract
1–14%), vitreitis (3–50%), and visual damage (50–100%).13,19–28
herefore, the results of the present study are in line with
ther Brazilian studies; however, it showed higher frequency
f symptomatic children at birth and with ocular manifesta-
ions than other studies carried out with children from Europe
nd North America.27 One possible explanation for this result
ay be the presence of more  virulent strains of T. gondii in
razil.29
The risk factors associated with the development of chori-
retinitis include female gender, brain calciﬁcations, and
elay of maternal treatment after seroconversion.18,30 In the
resent study, ocular injuries was neither associated with
hild gender nor with the presence of brain calciﬁcations.
In agreement with other studies conducted in the pre-
reatment period among Brazilian and American children,184;1 8(4):364–371 369
the present study showed that 55.2% of infants exhibited neu-
rological injuries in imaging exams, with calciﬁcation in 44.8%
of cases.
Asymptomatic infants at birth may progress with no infec-
tion sequelae, but may also develop visual damage, delayed
neuropsicomotor development, hydrocephaly, convulsions or
deafness months or years after birth.15,18,20 Sequelae were
identiﬁed in 68.9% of patients evaluated in this study, and the
most frequent sequelae were visual impairment and neuro-
logical damage.
One of the beneﬁts of treatment is the decrease in ocular
and neurological sequelae in T. gondii-infected children.18,31
Early treatment prevents ocular damage in children, as shown
in two longitudinal studies where a new lesion during the
follow-up was detected in 72% of untreated children compared
to 31% of treated children.32,33
Studies suggest that CT is more  sensitive than USG for
detecting brain calciﬁcations.34 However, a study comparing
brain CT and USG in 33 children with congenital toxoplasmo-
sis found 94% agreement between these imaging exams.35
In the present study, CT was more  sensitive for detecting
brain calciﬁcations, and USG was more  sensitive for detecting
hydrocephaly. However, speciﬁc treatment for toxoplasmosis
provided during the period between USG and CT evaluations
may have been responsible for missing hydrocephaly in CT
that was shown with USG. The majority of USG  evaluations
were performed during the ﬁrst month of life. The higher num-
ber of cases with brain calciﬁcations observed by CT compared
to those observed by USG may be explained by the natural
evolution of the CNS lesions.
Congenital toxoplasmosis can be transmitted by pregnant
women infected with HIV-1 who are those chronically infected
with T. gondii;29,36 there are also reported cases of CMV  and T.
gondii co-infection.15,37 In the present study, the four infants
co-infected with CMV showed clinical improvement when
ganciclovir was added to the speciﬁc therapy for toxoplas-
mosis. This result demonstrates the importance of excluding
other associated infections in patients with congenital toxo-
plasmosis.
Among the adverse effects of toxoplasmosis treatment,
the most harmful is neutropenia caused by the myelotoxic-
ity of sulfadiazine and pyrimethamine.15 In the present study,
severe and moderate neutropenia were observed in a few
cases, and the majority of them had been treated with other
myelotoxic drugs associated with toxoplasmosis treatment,
although all adverse effects were reversible with increased
folinic acid doses and temporary interruption of the treat-
ment. Reversible neutropenia was also observed in a cohort of
patients, evaluated from 1981 to 2004 in North America, with
daily doses of pyrimethamine for two or six months.31
In the present study, anti-T. gondii IgM seroprevalence was
lower than observed in previous studies that conﬁrmed T.
gondii infection by the detection of IgM antibodies in 50–75%
of newborns.15,22,38 The presence of anti-T. gondii IgG antibod-
ies in a newborn serum sample is not evidence of infection
because maternal IgG antibodies are passively transmitted.
The half-life of this immunoglobulin is 23 days and maternal
antibodies may persist in the newborn circulation for one year,
and about three months are necessary for a 10-fold reduc-
tion in titer. Therefore, anti-T. gondii IgG antibodies must be
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assayed in serial samples from the child to conﬁrm a congen-
ital infection.15,26 However, in the present study due to wide
variation (ranging from 1:16 to 1:128,000) serum anti-T. gondii
IgG was of little help to diagnose congenital disease. Other
serological methods are necessary to identify cases with false
negative results for anti-T. gondii IgM.
Although the quality of prenatal care for suspected cases
of toxoplasmosis in Londrina and northern Paraná in 2006
was not ascertained, a robust multi-professional team, with
the support of governmental institutions, started discussions
about this important public health problem, which resulted in
the implementation of the Surveillance Program of Congeni-
tal Toxoplasmosis, ﬁrst in the Basic Health Units of Londrina,
north of Paraná, and afterwards in other locations in Paraná
state.39,40 Its objective is to inform, standardize, and guide the
management of medical professionals in caring for pregnant
women with suspected or conﬁrmed toxoplasmosis and chil-
dren with congenital toxoplasmosis. To date, there has been
excellent adherence to the proposed program in the primary
health care units, decreasing the number of pregnant women
and children unnecessarily referred to reference centers for
diagnosis and treatment of toxoplasmosis by 63.9% and 42.6%,
respectively, at the University of Londrina Hospital. Further-
more, the incorrect use of sulfadiazine was decreased by 67.4%
after the program was implemented.39,40
Altogether, the results of the present study demonstrated
that from 2000 to 2010, the majority of pregnant women
whose children presented congenital toxoplasmosis and had
received care at the reference center for Pediatric Infectious
Diseases of the Outpatient Clinical Hospital of State Univer-
sity of Londrina, were given no treatment for toxoplasmosis
during the pregnancy because no diagnostic tests for toxo-
plasmosis had been requested. The majority of children were
symptomatic in the ﬁrst month of life, and chorioretinitis
was the most frequent ocular damage. A high frequency of
sequelae was also observed in this cohort of patients. These
data reinforce the importance of diagnosis and treatment of
toxoplasmosis acquired during pregnancy to reduce the occur-
rence of congenital toxoplasmosis and its complications in the
child. Continuous assessment, consolidation, and expansion
of the Surveillance Program of Congenital Toxoplasmosis39,40
can contribute to the improvement of health care for pregnant
women with suspected toxoplasmosis and for the reduction
of congenital toxoplasmosis in the Brazilian population.
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